Company intelligence / Profile preview
Amarantus BioScience
- Ownership
- Private
- Development stage
- Other
Overview
Amarantus developed biologics (notably MANF protein therapeutics) for neurodegenerative and regenerative indications, had positive early- and mid-stage clinical and preclinical results for Parkinson's, traumatic brain injury; licensed programs to Emerald in 2019 including near Phase 3-ready candidates; diagnostics for Alzheimer’s and MS were licensed/joint-ventured.[2][4][5]
- Therapeutic areas
- OphthalmologyPsychiatryDermatologyCardiovascularNeurology
- Modalities
- ProteinRecombinant proteinSmall moleculeEngineered skin substitute (biologic/device)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Amarantus BioScience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amarantus BioScience.